UNJHA FORMULATIONS LTD. (UNJHAFOR) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of UNJHA FORMULATIONS LTD. ₹31.69, price ₹33.00, upside -4.0%, quality 70 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹7.50 – ₹37.00 · fair‑value band ₹23.37 – ₹42.11 · the ₹33.00 price screens above the ₹31.69 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow UNJHA FORMULATIONS in your weekly email
Every Wednesday you see whether UNJHA FORMULATIONS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Unjha Formulations Limited engages in the manufacture and sale of ayurvedic products in India. It offers sat-isabgol and isabgo husk formulation in elaichi flavor under the Anchor name; and isabgol powder in orange flavor under the Fibron and Fibron SF names. The company also exports its products.
Show more
Unjha Formulations Limited engages in the manufacture and sale of ayurvedic products in India. It offers sat-isabgol and isabgo husk formulation in elaichi flavor under the Anchor name; and isabgol powder in orange flavor under the Fibron and Fibron SF names. The company also exports its products. Unjha Formulations Limited was incorporated in 1994 and is based in Sidhpur, India.
Stock analysis
UNJHA FORMULATIONS LTD. (UNJHAFOR) currently trades at ₹33.00, while our model-based Fair Value estimate is ₹31.69, so the stock looks roughly fairly valued today (gap 4.1%).
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹41.42 per share, and 13 of the 24 models we run sit above the ₹33.00 price.
Bear case: the Asset-Based group reads lowest at ₹5.75, and 11 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹23.37 (bear) to ₹42.11 (bull), the price of ₹33.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 70/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
UNJHA FORMULATIONS LTD. reported revenue of ₹156M in FY2026 versus ₹142M in FY2022, a compound +2.4%/yr. Reported net income was ₹7.0M in FY2026, compounding +29.3%/yr from FY2022.
Key figures
Market cap ₹148M (≈ $1.5M) · P/E ratio 31.4 · P/S ratio 1.42 · EPS (TTM) ₹1.05 · Net margin 4.5% · Return on equity 20.2% · Return on assets (EBIT) 11.4% · Operating margin 4.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 7% below its 52-week high and 88% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −4%, UNJHAFOR screens cheaper than that median.
Fair Value models
Bear ₹23.37Fair Value ₹31.69Bull ₹42.11
Price ₹33.00 · Upside -4.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 6 months old). Earnings retained since then (₹0.5408 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.87/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
What shareholders gained per year (last 5 years), in INR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+39.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+39.0%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 6%
2026 sits 150% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+7.4%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +3.1% a year for the price.
Compare UNJHA FORMULATIONS LTD. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score70 · Top 25%
Fair Value upside−4.0% · Above median
Profitability
Return on equity (TTM)20.2% · Top 25%
Return on assets10.0% · Top 25%
Net margin (TTM)3.1% · Below median
Operating margin (TTM)4.8% · Below median
Growth and dividend
Revenue growth−9.0% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is UNJHA FORMULATIONS LTD. (UNJHAFOR) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹31.69 versus a price of ₹33.00, about −4% upside (fairly valued).
What is the fair value of UNJHAFOR?
Our model-based fair value for UNJHA FORMULATIONS LTD. is ₹31.69 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹33.00.
What is the quality score of UNJHAFOR?
UNJHA FORMULATIONS LTD. has a Quality Score of 70/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for UNJHA FORMULATIONS LTD. (UNJHAFOR)?
Our model-based price target is the fair value of ₹31.69 (as of Oct 3, 2026) from 24 valuation models. Cautious scenario ₹23.37, optimistic scenario ₹42.11. It is a calculation from audited fundamentals, not an analyst target.
What is the UNJHA FORMULATIONS LTD. stock forecast for 2026?
Our models put fair value at ₹31.69, about −4% upside versus a price of ₹33.00 (fairly valued). Cautious scenario ₹23.37, optimistic scenario ₹42.11. The calculation is refreshed regularly with new filings.
What is the revenue of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
UNJHA FORMULATIONS LTD. reported trailing-twelve-month revenue of about ₹153M (latest available figure, as of Oct 3, 2026).
What growth is priced into UNJHA FORMULATIONS LTD. (UNJHAFOR)?
For today's price to be fair in a discounted-cash-flow model, UNJHA FORMULATIONS LTD. would have to grow free cash flow by +7.4 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.4 % per year. As of Oct 3, 2026.
What discount rate (WACC) does the fair value of UNJHAFOR use?
Our models discount UNJHA FORMULATIONS LTD. at 12.4 %: a base by market capitalisation (nano), country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For UNJHA FORMULATIONS LTD. that is +7.4 % per year a year over ten years, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has UNJHA FORMULATIONS LTD. (UNJHAFOR) delivered so far?
Over the past 5 years revenue at UNJHA FORMULATIONS LTD. grew +9.4 % a year. The price currently implies +7.4 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of UNJHA FORMULATIONS LTD. (UNJHAFOR) growing?
The median revenue growth in the sector is +3.7 % a year. That is the yardstick for the growth priced into UNJHA FORMULATIONS LTD. (+7.4 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
The free-cash-flow yield on the price is 6.82 %: that much free cash flow UNJHA FORMULATIONS LTD. produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For UNJHA FORMULATIONS LTD. it is ₹31.69 per share (as of Oct 3, 2026), against a price of ₹33.00. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is UNJHA FORMULATIONS LTD. stock overvalued or undervalued in 2026?
As of Oct 3, 2026, UNJHAFOR trades above its calculated fair value: price ₹33.00, fair value ₹31.69, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of UNJHAFOR?
No. The price is what the market pays today (₹33.00); the fair value is what the company's own numbers justify (₹31.69). For UNJHA FORMULATIONS LTD. the two are ₹1.31 per share apart. That gap is exactly why we show both numbers side by side.
How much is UNJHA FORMULATIONS LTD. worth?
The market values UNJHA FORMULATIONS LTD. at about ₹148M (market capitalisation, as of Oct 3, 2026). Per share that is ₹33.00; our models calculate a fair value of ₹31.69 per share.
What do the bullish and bearish scenarios say about UNJHAFOR?
Our models span a range for UNJHA FORMULATIONS LTD.: cautious scenario ₹23.37, base ₹31.69, optimistic ₹42.11 per share (as of Oct 3, 2026, price ₹33.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of UNJHAFOR?
UNJHA FORMULATIONS LTD. trades at a price-to-earnings ratio of 31.4 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹31.69 is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2019 to 2026), reported earnings: 18.2. Other multiples: P/B 3.9, P/S 1.0, EV/EBITDA 17.6.
How solid is the balance sheet of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
Balance-sheet figures for UNJHA FORMULATIONS LTD. (as of Oct 3, 2026): return on equity 20.2%. They feed the Quality Score of 70/100, which measures business quality independently of the share price.
How far is UNJHAFOR from its 52-week high?
UNJHA FORMULATIONS LTD. trades at ₹33.00, about 7% below its 52-week high of ₹35.45 and 88% above the low of ₹17.55 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹31.69 is for.
Which stocks are comparable to UNJHA FORMULATIONS LTD.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is UNJHA FORMULATIONS LTD. stock attractive at the current price?
The data as of Oct 3, 2026: price ₹33.00, calculated fair value ₹31.69 (−4%), Quality Score 70/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of UNJHAFOR calculated?
We run UNJHA FORMULATIONS LTD. through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹31.69, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. UNJHA FORMULATIONS LTD. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
The closing price on Oct 1, 2026 was ₹33.00. Our model-based fair value is ₹31.69, about −4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with UNJHA FORMULATIONS LTD. right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. A fairly wide model range (₹23.37 to ₹42.11) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Key figures of UNJHA FORMULATIONS LTD.
How large is the market capitalisation of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
The market capitalisation of UNJHA FORMULATIONS LTD. is ₹148M (≈ $1.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
The price-to-sales ratio of UNJHA FORMULATIONS LTD. is 1.42 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
Earnings per share at UNJHA FORMULATIONS LTD. are ₹1.05 (price ÷ EPS = P/E 31.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
The net margin of UNJHA FORMULATIONS LTD. is 4.5% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
The return on equity (ROE) of UNJHA FORMULATIONS LTD. is 20.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
On an EBIT basis the return on assets of UNJHA FORMULATIONS LTD. is 11.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of UNJHA FORMULATIONS LTD. (UNJHAFOR)?
The operating margin of UNJHA FORMULATIONS LTD. is 4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at UNJHA FORMULATIONS LTD. (UNJHAFOR)?
Revenue at UNJHA FORMULATIONS LTD. is growing −9.0% versus a year earlier (3y avg +5.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at UNJHA FORMULATIONS LTD. (UNJHAFOR)?
Earnings per share at UNJHA FORMULATIONS LTD. are growing −61.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch UNJHA FORMULATIONS LTD. in the live analysis
One click puts UNJHA FORMULATIONS LTD. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
